Evidence map›Paper›PMID 36512174›Full record

ArticleCancer reports (Hoboken, N.J.)2023

Screening for obstructive sleep apnoea in post-treatment cancer patients.

Harini Subramanian, Veronika Fuchsova, Elisabeth Elder, Alison Brand, Julie Howle, Anna DeFazio, Graham J Mann, Terence Amis, Kristina Kairaitis

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Harini SubramanianLudwig Engel Centre for Respiratory Research, The Westmead Institute for Medical Research, Westmead, Australia.
Veronika FuchsovaLudwig Engel Centre for Respiratory Research, The Westmead Institute for Medical Research, Westmead, Australia.
Elisabeth ElderWestmead Clinical School, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.
Alison BrandWestmead Clinical School, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.
Julie HowleWestmead Clinical School, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.
Anna DeFazioDepartment of Gynaecological Oncology, Westmead Hospital, Westmead, Australia.
Graham J MannMelanoma Institute Australia, The University of Sydney, Camperdown, Australia.
Terence AmisLudwig Engel Centre for Respiratory Research, The Westmead Institute for Medical Research, Westmead, Australia.
Kristina KairaitisLudwig Engel Centre for Respiratory Research, The Westmead Institute for Medical Research, Westmead, Australia.ORCID 0000-0002-8808-3183
The University of Sydney · AUAustralian National University · AUWestmead Institute for Medical Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsFor cancer patients, comorbid obstructive sleep apnea (OSA) poses additional risk to their surgical/anaesthetic outcomes, quality of life, and survival. However, OSA screening is not well-established in oncology settings. We tested two screening tools (STOP-Bang questionnaire [SBQ] and the at-home monitoring device, ApneaLink™Air), for predicting polysomnography (PSG) confirmed OSA in post-treatment cancer patients.

methodsBreast (n = 56), endometrial (n = 37) and melanoma patients (n = 50) were recruited from follow-up clinics at Westmead Hospital (Sydney, Australia). All underwent overnight PSG, 137 completed SBQ, and 99 completed ApneaLink™Air. Positive (PPV) and negative (NPV) predictive values for PSG-determined moderate-to-severe OSA and severe OSA, were calculated using an SBQ threshold ≥3 au and ApneaLink™Air apnoea-hypopnea index thresholds of ≥10, ≥15 and ≥30 events/h.

resultsBoth SBQ and ApneaLink™Air had high NPVs (92.7% and 85.2%-95.6% respectively) for severe OSA, but NPVs were lower for moderate-to-severe OSA (69.1% and 59.1%-75.5%, respectively). PPV for both tools were relatively low (all <73%). Combining both tools did not improve screening performance.

conclusionsThese screening tools may help identify cancer patients without severe OSA, but both are limited in identifying those with moderate-to-severe or severe OSA. PSG remains optimal for adequately identifying and managing comorbid OSA in cancer patients.

Indexed as

MelanomaSleep Apnea, ObstructiveEarly Detection of CancerHumansMass ScreeningQuality of Lifebreast cancercancer outcomesendometrial cancermelanomascreeningsleep apnea

Identifiers

PMID36512174
PMCPMC10026305
OpenAlexW4311290896

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read66
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.